FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a pharmaceutical combination for treating non-alcoholic fatty liver dystrophy. Described is a pharmaceutical combination for treating non-alcoholic fatty liver disease, comprising a pharmaceutical preparation based on a complex of silybin-phospholipid and Puer tea/Puer tea product, where the pharmaceutical preparation based on the silybin-phospholipid complex and Puer tea/Puer tea product are intended for placing into the same package after packaging separately in single doses, and they are intended for combined use in appropriate doses.
EFFECT: technical result is effective treatment of non-alcoholic fatty liver dystrophy.
12 cl, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VITAMIN E | 2016 |
|
RU2695806C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND RADIX PUERARIAE EXTRACT | 2016 |
|
RU2697670C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE | 2016 |
|
RU2699011C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN, VITAMIN E AND L-CARNITINE | 2016 |
|
RU2700793C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN | 2016 |
|
RU2697523C2 |
| USE OF PEGYLATED RECOMBINANT CHIMERIC MOUSE FIBROBLAST-21 GROWTH FACTOR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT IN COMPOSITION OF DRUGS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | 2018 |
|
RU2785582C2 |
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
| USE OF POLYDATINE FOR TREATING HEPATIC DISEASES AND POLYDATINE PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2468803C2 |
| PREVENTIVE AND THERAPEUTIC DRUG FOR NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2820552C2 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
